ClinicalTrials.gg
Not yet recruitingNCT07857317Updated Oct 5, 2026

Non-Contrast Versus Contrast-Enhanced MRI in Colorectal Liver Metastases

An observational study in Liver Metastases and Liver Neoplasms, sponsored by Assiut University. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Assiut University · Observational

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
40
Ages
18 Years and older
Sex
All
01

Study summary

This prospective study aims to compare the diagnostic performance of a non-contrast abbreviated MRI protocol with a contrast-enhanced MRI protocol for the detection and follow-up assessment of colorectal liver metastases.

Read the detailed description

Accurate detection and follow-up of colorectal liver metastases are essential for staging and treatment planning. This observational study will include patients with histologically confirmed colorectal adenocarcinoma and suspected hepatic metastases.

Each participant will undergo a non-contrast abbreviated MRI protocol followed by a contrast-enhanced MRI protocol using Gadodiamide during the same examination. Contrast-enhanced MSCT of the abdomen will serve as the reference standard. Treatment response will be assessed according to RECIST 1.1 on follow-up MRI.

02

Conditions studied

  • Liver Metastases
  • Liver Neoplasms

Browse trials for

Keywords

  • Colorectal liver metastases
  • Abbreviated MRI
  • Non-contrast MRI
  • Gadodiamide
  • Assiut
03

In context

Liver Neoplasms

1,348 studies on the registry are indexed under Liver Neoplasms; 337 are open to participants now.

This study's planned enrollment of 40 is below the median of 200 across 344 observational studies indexed under Liver Neoplasms.

Browse Liver Neoplasms studies →

Lead sponsor

Assiut University is the lead sponsor of 5,094 studies on the registry; 2,187 are open to participants now.

Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with histologically confirmed colorectal adenocarcinoma and suspected hepatic metastases referred to the Diagnostic and Interventional Radiology Department at Assiut University Hospitals.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • - confirmed colorectal adenocarcinoma
  • One or more hepatic focal lesions known or suspected to represent colorectal liver
  • Adequate image quality allowing reliable assessment of hepatic lesions
  • Patients scheduled to receive chemotherapy allowing assessment of treatment response
  • Patients referred for initial staging, restaging, or evaluation of treatment response
  • Written

Exclusion criteria

Exclusion Criteria:

  • - to gadolinium-based contrast administration
  • Incomplete MRI examinations
  • Inadequate image quality preventing reliable assessment
  • Contraindications to MRI examination
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No

Groups and cohorts

  • Single cohort: Patients with Colorectal Liver Metastases

    Patients with confirmed colorectal adenocarcinoma and suspected hepatic metastases who will undergo both non-contrast and contrast-enhanced MRI protocols during the same examination.

06

What researchers measure

Primary outcomes

  1. Sensitivity of non-contrast MRI for detection of hepatic metastases

    Sensitivity of the non-contrast abbreviated MRI protocol for detection of hepatic metastases, using contrast-enhanced MSCT as the reference standard.

    Time frame: Baseline

Secondary outcomes

  1. Sensitivity of contrast-enhanced MRI for detection of hepatic metastases

    Sensitivity of the contrast-enhanced MRI protocol for detection of hepatic metastases, using contrast-enhanced MSCT as the reference standard.

    Time frame: Baseline

  2. Specificity of non-contrast MRI

    Specificity of the non-contrast abbreviated MRI protocol for detection of hepatic metastases.

    Time frame: Baseline

  3. Specificity of contrast-enhanced MRI

    Specificity of the contrast-enhanced MRI protocol for detection of hepatic metastases.

    Time frame: Baseline

  4. Number of hepatic lesions detected by non-contrast MRI

    Mean number of hepatic metastatic lesions detected by the non-contrast MRI protocol.

    Time frame: Baseline

  5. Number of hepatic lesions detected by contrast-enhanced MRI

    Mean number of hepatic metastatic lesions detected by the contrast-enhanced MRI protocol.

    Time frame: Baseline

  6. Proportion of patients with partial response according to RECIST 1.1

    Proportion of patients classified as partial response according to RECIST 1.1 on follow-up MRI.

    Time frame: At 3 months

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.

Of 132 non-industry observational studies under Liver Neoplasms, half reached primary completion within 114 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 172. This study's planned 12 months is below that.

Counting every sponsor, half of 160 studies reached it within 59 months; a quarter within 34 and three quarters within 172.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2026
First posted
Oct 5, 2026
StartEst.
Sep 27, 2026
Primary completionEst.
Sep 27, 2027
CompletionEst.
Mar 20, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07857317
Lead sponsor
Assiut University
Responsible party
Mina Mohsen William Basta (Resident Physician, Department of Diagnostic and Interventional Radiology, Assiut University) — Principal investigator
First posted
Oct 5, 2026
Start date
Sep 27, 2026 (estimated)
Primary completion
Sep 27, 2027 (estimated)
Completion
Mar 20, 2028 (estimated)
Last update
Oct 5, 2026

Study contacts

Mina M William, Resident
Contact
mina.18313293@med.aun.edu.eg
01273242181
Amr F Mourad, prof
study chair · Diagnostic and Interventional Radiology Department, Assiut University Hospitals

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion